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ABSTRACT 
Background. Tisotumab vedotin (TV; HuMax-TF-ADC), is a first-in-class antibody-drug 
conjugate directed against tissue factor (TF), which is expressed across multiple solid tumor 
types and is associated with poor clinical outcomes. The primary objective of this study was to 
establish the tolerability of TV in a mixed population of patients with specified solid tumors. 
Methods. InnovaTV 201 is a phase 1/2 open-label, dose-escalation and -expansion study 
evaluating the safety, tolerability, pharmacokinetics (PK) profile, and antitumor activity of TV in 
patients with locally advanced and/or metastatic solid tumors known to express TF. Patients were 
aged ≥18 years and had an ECOG PS of 0-1. No specific TF expression level was required for 
inclusion. In the dose-escalation phase, patients were treated with TV between 0∙3 and 2∙2 mg/kg 
intravenously once every 3 weeks in a traditional 3 + 3 design to determine the maximum-
tolerated dose (MTD) and recommended phase 2 dose (RP2D). Plasma was collected to 
characterize the PK profile of TV. In the dose-expansion phase, patients were treated at the 
RP2D in seven advanced solid tumor-type cohorts, including bladder, cervix, endometrium, 
esophagus, lung, ovarian, and prostate cancers. The primary endpoint of the study was the 
incidence of adverse events, which was analyzed in all patients who received at least one dose of 
TV. This study is registered with ClinicalTrials.gov, number NCT02001623, and is closed to 
new participants with follow-up ongoing. 
Findings. In the dose-escalation phase, 27 patients with advanced solid tumors received TV in 
eight sequential dose cohorts between 0∙3 and 2∙2 mg/kg. Dose-limiting toxicities, including 
grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were observed at TV 2∙2 
mg/kg. TV at 2∙0 mg/kg was identified as the MTD and the RP2D. The PK profile of TV was 
dose proportional. In the dose-expansion phase, 147 patients with solid tumors were treated with 
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TV at 2∙0 mg/kg. The most common (≥20%) treatment-emergent adverse events (AEs) of any 
grade included epistaxis (102 [69∙4%] of 147 patients), fatigue (82 [55∙8%]), nausea (77 
[52∙4%]), alopecia (64 [43∙5%]), conjunctivitis (63 [42∙9%]), decreased appetite (53 [36∙1%]), 
constipation (n=52 [35∙4%]), diarrhea (44 [29∙9%]), vomiting (42 [28∙6%]), neuropathy 
peripheral (33 [22∙4%]), dry eye (32 [21∙8%]), and abdominal pain (30 [20∙4%]). The most 
common AEs of ≥3 grade included fatigue (14 [9∙5%] of patients), anemia (8 [5∙4%]), abdominal 
pain (6 [4∙1%]), hypokalemia (6 [4∙1%]), conjunctivitis (5 [3∙4%]), hyponatremia (5 [3∙4%]), and 
vomiting (5 [3∙4%]). Treatment-emergent serious AEs (SAE) occurred in 67 (45∙6%) of 147 
patients; a total of 39 (26∙5%) of 147 patients experienced a treatment-emergent SAE related to 
the study drug. Across tumor types, the confirmed ORR was 15∙6% (95% CI: 10∙2%–22∙5%; 23 
of 147 patients).  
Interpretations. TV demonstrated a manageable safety profile with encouraging preliminary 
antitumor activity across multiple tumor types in heavily pretreated patients. Based on these data, 
continued evaluation of TV is warranted in solid tumors.  
Funding. Genmab A/S.  
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RESEARCH IN CONTEXT 
Evidence before the study 
We performed a search through August 19, 2018 to identify all clinical studies evaluating the use 
of tissue factor (TF)-targeting therapeutics in patients with cancer. Our search included PubMed 
and used the following search terms: “tissue factor,” or “thromboplastin,” or “CD142.” TF is 
broadly expressed across multiple solid tumor types and contributes to cancer biology by 
promoting metastasis, tumor growth and tumor angiogenesis, suggesting that it may be a 
potential target for therapeutic intervention. Our search revealed that no studies have been 
published on the safety and activity of TF-targeting agents in patients with cancer; although two 
early phase clinical trials evaluated agents in patients with macular degeneration or acute lung 
injury. 
Added value of this study 
To our knowledge, this is the first study assessing the safety, tolerability, pharmacokinetics, and 
preliminary activity of a TF-targeting agent, tisotumab vedotin (TV), in patients with cancer. In 
this phase 1/2 study, TV demonstrates a manageable safety profile and preliminary activity in 
patients with advanced solid tumors, including bladder, cervix, endometrium, esophagus, lung, 
and ovary. 
Implications of all the available evidence 
The prognosis for patients with advanced solid tumors remains poor and there is an unmet need 
for new treatments to improve outcomes. The present trial confirms the feasibility and 
preliminary clinical activity of tisotumab vedotin, a TF-targeting antibody drug conjugate, in 
patients with locally advanced and/or metastatic solid tumors known to express TF. Further 
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studies are required to confirm this activity and assess in which patients TV is most likely to be 
effective.   
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INTRODUCTION 
Tisotumab vedotin (TV) is a first-in-class antibody-drug conjugate (ADC) that is directed against 
tissue factor (TF) expressed on the cell surface of tumor cells to deliver a clinically validated 
toxic payload to tumors.1,2 TV is comprised of a fully human monoclonal antibody specific for 
TF conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a 
protease-cleavable valine-citrulline linker.1  
TF is a transmembrane glycoprotein that functions as the main initiator of the TF pathway of 
blood coagulation, also known as the extrinsic coagulation pathway.3,4 Beyond its function in 
coagulation, TF has cell-signaling properties.5 TF, in complex with its physiological ligand 
FVIIa, can activate protease-activated receptor 2, resulting in an intracellular-signaling cascade 
that tumors can exploit to promote malignant-cell survival, tumor growth, angiogenesis, and 
metastasis.3,5,6 The role of TF in cancer biology is underscored by its aberrant expression in a 
broad range of solid tumors. For example, high percentages of TF-positive tumor biopsies, as 
assessed by immunohistochemistry, were observed in cervical cancer (100%), non-small cell 
lung cancer (34–88%), endometrial cancer (14–100%), prostate (47–75%), ovarian cancer (75–
100%), esophageal cancer (43–91%), and bladder cancer (78%).7–18 The expression of TF is 
enhanced in cancer through oncogenic events, such as constitutive activation of the MAPK- and 
PI3K-signaling pathways, hypoxia-induced signaling, and loss of tumor suppressor genes.3 TF 
expression levels have been associated with poor clinical outcomes and higher metastatic 
potential in multiple solid tumor types.6,18,19 Treatment options for many of these solid tumors 
remain limited and, especially in the context of metastatic and refractory disease, are often 
hampered by poor efficacy and/or significant toxicities. There is an urgent unmet medical need 
for more effective and tolerable treatment alternatives for patients with these types of cancer. 
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Given its differential expression in many cancers as well as its role in cancer biology, TF is a 
rational target for the development of therapeutics to help address this unmet need and the 
potential to improve patient outcomes across a broad range of solid tumors. 
The antibody moiety of TV, HuMax-TF, was selected from a panel of TF-specific human 
monoclonal antibodies based on high affinity binding to TF (low nM range) and the capacity for 
interfering with protease activated receptor 2 (PAR-2) intracellular signaling, as assessed by 
inhibition of TF:FVIIa-dependent ERK phosphorylation and interleukin (IL)-8 production in TF-
positive tumor cells. Internalization studies in vitro demonstrated that HuMax-TF was efficiently 
internalized upon binding to TF-positive tumor cells. At the same time, HuMax-TF showed 
minimal impact on TF procoagulant activity in vitro, as assessed using a chromogenic FXa 
generation assay and thromboelastography (TEG) analysis.1 Importantly, HuMax-TF, which 
showed comparable binding to human and cynomolgus monkey TF, did not induce clear effects 
on parameters of coagulation at very high doses (up to 100 mg/kg) in cynomolgus monkeys. 
Tisotumab vedotin induces potent cytotoxicity in TF-positive tumor cells in vitro and was shown 
to be the most potent of three different TF-specific MMAE-based antibody-drug conjugates in 
preclinical tumor models in vivo. The dominant mechanism of action of tisotumab vedotin in 
preclinical models was found to be MMAE-mediated tumor cell killing. Upon binding of TF by 
TV, the resulting complex is efficiently internalized and trafficked to the lysosome where the 
linker is enzymatically cleaved, releasing MMAE within the targeted tumor cell.1,20 Then 
MMAE binds to tubulin and disrupts microtubule polymerization, resulting in G2/M cell cycle 
arrest and apoptosis.1,21 As a cell-permeable molecule, MMAE can also diffuse into the tumor 
microenvironment where it might induce bystander killing of neighboring dividing cells.1,20 
These antitumor effects are further enhanced by the capacity of TV to bind FcγRIIIa on adjacent 
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natural killer cells, which was shown to lead efficient to antibody-dependent cellular cytotoxicity 
of TF-expressing tumor cells.1,22 Additionally, MMAE-based ADCs have been shown to induce 
immunogenic cell death, which can activate innate and adaptive immune responses to tumor 
antigen.23 In preclinical studies, TV has demonstrated robust antitumor activity in vitro and in 
xenograft models in vivo, using models derived from multiple solid tumors, including bladder, 
prostate, lung, pancreas, ovarian, and cervical, which demonstrated differential expression of 
TF.1  
These preclinical data led to the conduct of the first-in-human TV clinical trial: innovaTV 201 
(NCT02001623), which evaluated the safety, tolerability, pharmacokinetics, and antitumor 
activity of TV in patients with locally advanced and/or metastatic solid tumors known to express 
TF are presented.24 The results of this trial are presented herein; patients with tumor types known 
to express TF and with susceptibility to microtubule disrupting agents were evaluated. 
METHODS 
Study Design and Participants 
This study was conducted as a phase 1/2, open-label, multicenter, dose-escalation and dose-
expansion study. Patients were recruited across 3 sites (Denmark [n=1]; United Kingdom [n=1], 
United States [n=1]) for the dose-escalation portion and 21 sites (Belgium [n=6]; Denmark 
[n=2]; Sweden [n=1]; United Kingdom [n=9]; United States [n=3]) for the expansion portion 
(Appendix p 2). Eligible patients had locally advanced and/or metastatic cancer of the bladder, 
cervix, endometrium, esophagus, non-small cell lung cancer (NSCLC), ovary, prostate (in 
particular castration-resistant prostate cancer [CRPC]), or squamous cell carcinoma of the head 
and neck (SCCHN) who had failed or were not eligible to receive the available standard of care. 
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Eligible patients were aged ≥18 years, had a life expectancy ≥3 months, acceptable organ 
function, hematologic and coagulation status, Eastern Cooperative Oncology Group performance 
status of 0 or 1, and measurable disease according to Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1∙1.25 Patients with prostate cancer could be included based on bone 
metastases or prostate specific antigen (PSA). All patients were required to have a tumor biopsy 
at screening; a fresh biopsy was collected at least 2 weeks before dosing, if no archival tissue 
was available. There were no requirements for tumor TF expression for eligibility. 
Patients were excluded if they had past or current coagulation defects, ongoing major bleeding, 
long-term antiplatelet or anticoagulant therapy, clinically significant cardiac disease, major 
surgery within 6 weeks before drug infusion or anticipated during study treatment, open biopsy 
within 7 days before drug infusion, had another malignancy, or known infection with HIV, 
hepatitis B virus, or hepatitis C virus. Patients were also excluded if they had received prior 
therapy with an auristatin derivative, bevacizumab within 12 weeks from first study dose, 
radiotherapy within 28 days from first study dose, or any other anticancer therapy within five 
half-lives before first dose. 
The study protocol was amended on 22 December 2016 and again on 23 June 2017 after 77 
patients were enrolled to implement ocular preventive measures, including the use of lubricating 
eye drops throughout the study period, steroid eye drops during the first 3 days of each treatment 
cycle, local ocular vasoconstrictor before treatment infusion, and cooling eye masks worn during 
treatment infusion, as well as stricter dose adjustment guidance. 
The Independent Ethics Committee (IEC) or Institutional Review Board (IRB) at each study site 
approved the protocol, and the study was conducted in accordance with the Declaration of 
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Helsinki and Good Clinical Practice Guidelines. All patients provided written informed consent 
for participation. 
Procedures 
The dose-escalation phase of this clinical trial was conducted using a traditional 3 + 3 design. 
Nonclinical safety studies were conducted in cynomolgus monkeys that were treated with 
tisotumab vedotin at doses ranging from 1–5 mg/kg. First-in-human dose of 0.3 mg/kg was 
selected based on 1/10 highest non-severely toxic dose (HNSTD) for TV of 3 mg/kg determined 
in the pivotal 13 weeks good laboratory practice (GLP)-repeat dose toxicity study (Q3W x 5 
doses) in cynomolgus monkeys. Based on adverse events observed in these studies, particularly 
reversible bone marrow toxicity and low neutrophil counts that showed a nadir between 10 and 
18 days after treatment, the Q3W dosing schedule was selected. Patients were enrolled to eight 
cohorts of TV, ranging from 0∙3 to 2∙2 mg/kg administered intravenously once every 3 weeks 
(1Q3W). The decision to proceed to the next dose level in the dose-escalation phase was based 
on the rate of dose-limiting toxicities (DLT) observed during the first 21-day treatment cycle. If 
one of the three patients at a given dose developed a DLT, then an additional three patients were 
added at the same dose level. If none of the three patients, or one of six developed a DLT, then 
the study continued escalation to the next dose level. The dose level below the dose at which two 
or more DLTs occurred within six patients was defined as the MTD, and the RP2D.  
The dose-expansion phase of the study had a multiple cohort design and enrolled patients in 
tumor-type cohorts to be treated with TV at the RP2D. Patients were treated for up to four cycles 
or until disease progression. Recruitment was initiated in five tumor cohorts, including bladder, 
cervix, endometrium, ovary, and prostate. Following a safety review of data from the ten first 
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patients recruited and followed for at least one cycle, regardless of indication, recruitment for the 
lung and esophageal cohort was initiated. Based on preliminary activity data, the cervical and 
ovarian cohorts were expanded to include a maximum of approximately 55 and 30 patients, 
respectively. The remaining tumor cohorts recruited approximately 14 patients each. Patients 
with demonstrated clinical benefit, defined as stable disease or better, had the option to continue 
treatment for an additional eight cycles or until unacceptable toxicity or disease progression. 
Adverse events (AEs) were assessed and reported at each visit according to the Common 
Toxicity Criteria for Adverse Events (CTCAE) version 4∙03. Tumor assessments were performed 
using computed tomography or by magnetic resonance imaging in patients allergic to iodine 
contrast or at the discretion of the investigator, at screening and every 6 weeks during the study.  
Blood samples for PK analysis were collected before and after the infusion at each cycle. 
Additional samples were collected during cycles 1 and 2 on day 1 (2 hours, 5 hours, and 12 hours 
after the end of the infusion) and on days 2, 8, and 15. Blood samples were collected throughout 
the study for analysis of blood coagulation parameters, including prothrombin time (PT) and 
activated partial thromboplastin time (aPTT) and immunogenicity.  
Outcomes 
The primary objective of this study was to establish the safety and tolerability of TV, 
characterized by the incidence of AEs, serious AEs, infusion-related AEs, CTCAE grade ≥3 
AEs, and study drug related AEs. A serious AE (SAE) was defined as any AE that required an 
extended hospitalization, resulted in persistent or significant incapacity/dysfunction, led to a 
congenital anomaly or birth defect, was deemed medically important, resulted in death, or was 
fatal or life-threatening. Safety laboratory parameters and safety events of interest, including skin 
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disorders, bleeding events, and neuropathy were included in the safety analysis. A data-
monitoring committee (DMC) evaluated safety data during the study. Causality for DLTs was 
assessed by the investigators and sponsor in collaboration with the DMC. 
Secondary objectives were to establish the maximum-tolerated dose (MTD), to define the 
recommended phase 2 dose (RP2D), to characterize the pharmacokinetic (PK) profile, and to 
assess the antitumor activity of TV. PK parameters, including area under the concentration time 
curve (AUC0-t), maximum concentration (Cmax), and time to reach maximum concentration (tmax), 
were determined from the concentration-time data, where feasible, for TV and free MMAE by 
noncompartmental analysis.  
Tumor response was investigator assessed per RECIST version 1∙1 criteria, with antitumor 
activity endpoints including objective response (complete response [CR] or partial response 
[PR]), disease control (CR, PR, or SD), progression-free survival (PFS), and duration of response 
(DoR). PFS was defined as the number of days from the first day of the first cycle to the first 
progressive disease (PD) or death. Deaths that occurred within 60 days of the last visit were 
included in the analysis. DoR was defined as the number of days from the first documented 
objective tumor response (CR or PR) to the date of first PD or death. Changes in prostate specific 
antigen (PSA) and cancer antigen (CA) 125 were also monitored where applicable.  
Statistical Analyses  
The sample size of the dose-escalation phase was calculated as a maximum of 48 patients based 
on the 3 + 3 design with three to six patients in each dose cohort. The estimated sample size for 
the dose-expansion phase was 144 patients, which had 76% and 95% power to detect AEs with 
incidences 1% and 2% respectively. Based on preliminary activity data within the cervical and 
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ovarian cohorts, the study protocol was amended on 26 September 2017 to allow for the 
expansion of these cohorts causing the study to exceed the original sample size estimates. 
The full analysis population was comprised of patients who were exposed to study drug. This 
population was used for evaluation of all endpoints. Safety evaluations and PK parameters were 
summarized descriptively. For the activity analysis, the investigator-assessed objective response 
rate (ORR) was determined with the corresponding two-sided 95% exact binomial CI. The 
Kaplan-Meier (KM) method was used to estimate the median months for progression-free 
survival (PFS) and duration of response (DoR), which were presented with a two-sided 95% CI. 
Further exploratory analysis of subsets of data may be performed in preparation for subsequent 
studies. Data analysis was performed using SAS (version 9.4) and R (version 3.5.1). This study 
is registered with ClinicalTrials.gov, number NCT02001623.24 
Role of the Funding Source 
The funder designed the study in collaboration with a subgroup of investigators, managed the 
clinical trial database, including oversight of data collection, performed statistical analyses, and 
provided medical writing assistance. The corresponding author had full access to all the data in 
the study and had the final responsibility to submit for publication. 
RESULTS 
This report includes data from the completed dose-escalation phase and the ongoing (data cutoff 
date of February 1, 2018, except for the cervical cohort activity analysis, which has a cutoff date 
of July 24, 2017) expansion phase of the innovaTV 201 study. The dose-escalation phase 
enrolled 27 patients between 9 December 2013 and 18 May 2015, with a mixed population of 
primary tumor types. Three patients were included in dose cohorts ranging from 0∙3 to 2∙0 
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mg/kg, while six patients were included in the 2∙2-mg/kg dose cohort. The median age of 
patients was 62 (interquartile range [IQR] 58–67) years. The median number of prior therapies 
was 3 (1–14). In the dose-expansion phase, 147 patients were included across seven tumor-type 
cohorts, including bladder (n=15), cervical (n=34), endometrial (n=14), esophageal (n=15), 
NSCLC (n=15), ovarian (n=36), and prostate (n=18) between 8 October 2015 and 26 April 2018. 
The median age of patients was 59 (IQR 52–67) years. The median number of prior therapies 
across tumor types ranged was 3 (1–9). Patient characteristics are listed in Table 1. Patient 
enrollment and disposition are illustrated in Figure 1.  
In the dose-escalation phase, all 27 patients received ≥1 dose of TV and were evaluable for 
DLTs. Three DLTs were identified in the 2∙2-mg/kg dose cohort, including type 2 diabetes 
mellitus, mucositis, and neutropenic fever, all of which were grade 3. Based on these data, the 
MTD and RP2D were defined as 2∙0 mg/kg. There were three deaths reported; none of which 
were considered related to study drug. Two patients included in the 0∙3-mg/kg dose cohort died 
from disease progression; one patient (SCCHN) included in the 0∙6-mg/kg dose cohort died from 
a pharyngeal tumor hemorrhage. Treatment-emergent AEs for the dose-escalation phase are 
listed in Appendix p 3. 
In the dose-expansion phase, 147 patients received ≥1 dose of TV and were evaluated for safety. 
Of the 147 patients treated, 27 (18%) required 1 or more dose reductions. The median (IQR) 
follow-up time in these patients was 2∙8 (1∙4–4∙4) months. Across tumor types, the most 
commonly (occurring in ≥20% of patients) reported treatment-emergent AEs (TEAEs) of any 
grade were epistaxis (102 [69∙4%] of 147 patients), fatigue (82 [55∙8%]), nausea (77 [52∙4%]), 
alopecia (64 [43∙5%]), conjunctivitis (63 [42∙9%]), decreased appetite (53 [36∙1%]), constipation 
(52 [35∙4%]), diarrhea (44 [29∙9%]), vomiting (42 [28∙6%]), neuropathy peripheral (33 [22∙4%]), 
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dry eye (32 [21∙8%]), and abdominal pain (30 [20∙4%]) (Table 2). Treatment-emergent grade ≥3 
AEs occurred in 83 (56∙5%) of 147 patients. The most commonly (occurring in >2% of patients) 
reported treatment-emergent grade ≥3 AEs were fatigue (14 (9∙5%) of 147 patients), anemia (8 
[5∙4%]), abdominal pain (6 [4∙1%]), hypokalemia (6 [4∙1%]), conjunctivitis (5 [3∙4%]), 
hyponatremia (5 [3∙4%]), and vomiting (5 [3∙4%]). A total of 60 (40∙8%) of 147 patients 
experienced a treatment-emergent grade ≥3 AE deemed related to study drug.  
Treatment-emergent SAEs occurred in 67 (45∙6%) of 147 patients. The most common treatment-
emergent SAEs (occurring in >2% of patients) were vomiting (6 [4∙1%]), abdominal pain (5 
[3∙4%]), and anemia (4 [2∙7%]) (Appendix p 4). A total of 39 (26∙5%) of 147 patients 
experienced a treatment-emergent SAE deemed related to study drug. Discontinuations related to 
AEs occurred in 32 (21∙8%) of 147 patients, ocular AEs occurred in 11 (7∙5%) patients. Six AEs 
with fatal outcomes occurred in the dose-expansion phase: two patients with general physical 
health deterioration, one with disease progression, one with metastasis to the central nervous 
system, one with esophageal metastatic cancer, and one with pneumonia. These events were 
deemed not related to study drug, with the exception of pneumonia, which was possibly related. 
AEs of special interest included bleeding-related events, neuropathy, and ocular events 
(conjunctivitis, ulceration, keratitis, symblepharon). Epistaxis was the most commonly reported 
AE, the majority of which were grade 1 in severity (100 of 102). No grade 4–5 bleeding events 
were reported in the dose-expansion phase. Neuropathy of any grade occurred in 63 (42∙9%) of 
147 patients with 10 (6∙8%) patients experiencing grade ≥3 neuropathy (Appendix p 5). The 
median (SD) time to onset of neuropathy was 8∙7 (0∙1–26∙4) weeks. In patients who experienced 
neuropathy, 81% (51 of 63) of patients had received prior taxane chemotherapy, the most 
common of which was paclitaxel. At the time of this analysis, 15∙9% (10 of 63) of patients had 
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neuropathy events resolved, including seven patients with prior taxane. Ocular events of any 
grade occurred in 88 (59∙9%) of 147 patients, with 63 (42∙9%) of all patients experiencing 
conjunctivitis (Appendix p 6). Implementation of ocular mitigation strategies substantially 
reduced the incidence of conjunctivitis, which decreased from 43 (55∙8%) of 77 patients to 20 
(28∙6%) of 70 patients (Appendix p 6). 
The PK profile of TV was assessed in the dose-escalation phase. The profiles of mean blood 
concentration for TV and free MMAE are presented in the Appendix p 9. Increases in exposure 
to TV and free MMAE were proportional to dose. The Cmax of TV occurred shortly after the end 
of infusion, whereas levels of free MMAE peaked 1 week following infusion. Only low levels of 
free MMAE were detected in the systemic circulation. Parameters reflecting exposure, including 
Cmax and AUC0-t, increased proportionally over the dose ranges examined (Appendix p 7). When 
TV was dosed at 2∙0 mg/kg (n=3), the mean Cmax value was 32∙3 µg/mL and the mean AUC0-t 
value was 1256∙4 h·µg/mL. Following a single-dose administration of TV at 2∙0 mg/kg, the 
mean time-to-peak plasma concentration (tmax) was observed 1∙2 hours from the start of the 
infusion. The mean (SD) half-life for TV at 2∙0 mg/kg was estimated to be 1∙71 (0∙20) days.   
Blood coagulation parameters, including PT and aPTT, were not altered by treatment with TV 
(Appendix p 10). Across dose-escalation cohorts, the mean (SD) PT value at baseline was 11∙5 
(1∙3) seconds (n=18) compared with 11∙7 (1∙5) seconds (n=17) at study completion, while the 
mean (SD) aPTT value at baseline was 28.2 (3∙3) seconds (n=25) compared with 27∙1 (3∙2) 
seconds (n=23) at study completion. 
In the dose-escalation phase, of the 27 patients evaluated, one patient with metastatic cervical 
cancer achieved a partial response at the 1.2 mg/kg dose level (antitumor activity reported in 
Appendix p 8). This patient had received three prior treatment lines before study entry. In the 
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dose-expansion phase, 147 patients were evaluable for investigator-assessed response. Across 
tumor types, the confirmed ORR for the full analysis set was 15∙6% (95% CI: 10∙2%–22∙5%; 23 
of 147 patients). All responses were partial. For each tumor type, the confirmed ORR was 26∙7% 
(4/15) in bladder, 26∙5% (9/34) in cervical, 13∙9% (5/36) in ovarian, 13∙3% (2/15) in esophageal, 
13∙3% (2/15) in NSCLC, 7∙1% (1/14) in endometrium, and 0/18 in prostate (Table 3). Maximum 
percentage change from baseline in tumor size for each dose-expansion cohort is shown in 
Figure 2. Across tumor types, the median confirmed DoR was 5∙7 (3∙0–9∙5) months (swimmer 
plots for individual responders [Figure 3]) and the median PFS was 3∙0 (2∙8–4∙1) months with 
89 events.  
DISCUSSION 
This multicenter, first-in-human clinical trial has validated the targeting of TF for the treatment 
of advanced cancer, and has shown that TV has an encouraging antitumor activity in heavily 
pretreated patients with multiple different tumors known to express TF. The safety profile of TV 
2∙0 mg/kg 1Q3W was generally consistent with other MMAE-based ADCs, although epistaxis 
and conjunctivitis were reported at increased incidences with TV. Bleeding events other than 
epistaxis were consistent with those expected for a population of patients treated with 
chemotherapy indicating that epistaxis was not a signal for a general bleeding disorder. Ocular 
toxicities have been reported with ADCs that include ravtansine (DM4) and monomethyl 
auristatin F (MMAF); however, they are rarely described for ADCs that utilize MMAE.26 As a 
result, it is speculated that the increased incidences of epistaxis and conjunctivitis are related to 
underlying inflammation or increased localized TF expression in the affected area. An ocular 
mitigation plan was implemented during the study that reduced the frequency and severity of 
ocular AEs, including conjunctivitis. Similar ocular mitigation strategies have been used 
18 
 
prophylactically with other ADCs to manage ocular events. Peripheral neuropathy, a known 
toxicity of MMAE-based ADCs, was observed in patients treated with TV; most events reported 
were mild to moderate in severity and occurred in patients with prior exposure to taxanes. Three 
DLTs were reported in the 2∙2-mg/kg dose cohort of the dose-escalation phase, one of which was 
type 2 diabetes mellitus. Hyperglycemia has been previously described as a DLT in other 
MMAE-based ADCs, such as brentuximab vedotin and DMOT4039A, and is likely to be due to 
the cytotoxic payload.27,28 
This trial validates the use of an ADC-based approach to target TF, the main initiator of the 
extrinsic pathway of blood coagulation.4 Coagulation parameters, such as PT and aPTT, were not 
affected by TV administration. Furthermore, despite the incidence of grade 1–2 epistaxis in 
69∙4% of patients receiving TV, no grade 4–5 bleeding events were observed in patients in the 
dose-expansion phase. These findings corroborate previous nonclinical toxicology studies of TV 
in cynomolgus monkeys, which demonstrated no significant impact on functional bleeding time 
or systemic parameters of coagulation at doses up to 5 to 6 mg/kg.1  
Although not designed or powered to assess antitumor activity, this trial reports encouraging 
antitumor activity for TV in a broad population of patients with heavily pretreated, locally 
advanced and/or metastatic cancers of the bladder, cervix endometrium, esophagus, lung, and 
ovary. Biopsy or archived samples were collected at study entry for all patients, and a currently 
ongoing analysis will assess the correlation of tumor TF expression and the antitumor activity of 
TV to assess the value of TF expression as a biomarker for treatment response. 
These data support the further investigation of TV. Multiple studies are underway, including 
innovaTV 207 and innovaTV 204. InnovaTV 207 (NCT03485209) is an ongoing phase 2 study 
evaluating the activity, safety, and tolerability of TV monotherapy administered every 3 weeks in 
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patients with relapsed, locally advanced or metastatic colorectal cancer, squamous NSCLC, 
pancreatic cancer, or SCCHN.29 Based on encouraging preliminary activity seen in the cervical 
cancer cohort, innovaTV 204 (NCT03438396) is an ongoing phase 2 study evaluating the 
activity, safety, and tolerability of TV monotherapy in patients with previously treated, recurrent 
or metastatic cervical cancer that had progressed during or after treatment with standard first-line 
therapy.30 
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FIGURE LEGENDS 
Figure 1. Patient enrollment and disposition in innovaTV 201 (dose escalation and expansion). 
 
Figure 2. Maximum reduction in tumor size in the various expansion study cohorts recruiting 
patients with bladder, cervix, endometrium, esophagus, NSCLC, ovary, and prostate cancers.  
The black bars indicate tumor size at first scan, and the gray bars indicate best response. 
*Target lesions were lymph nodes only and the sum of the target lesions post-baseline was <10 
mm. The percentage change from baseline was set to -100. †Disease progression due to new 
lesion. ‡Percent change from baseline is 287∙5%. 
 
Figure 3. Duration of response in individual responders.  
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Table 1. Patient Characteristics  
Characteristic Dose Escalation Dose Expansion 
Total patients, No. 27 147 
Age, median (IQR), y 63 (58–67)  59 (52–67) 
Female, No. (%) 18 (66∙7) 101 (68∙7) 
Male, No. (%) 9 (33∙3) 46 (31∙3) 
Race  
White 
Black 
Asian 
Other 
Missing 
 
27 (100) 
0 
0 
0 
0 
 
136 (92∙5) 
2 (1∙4) 
4 (2∙7) 
3 (2∙0) 
2 (1∙4) 
ECOG PS, No. (%) 
0 
1 
Missing 
 
13 (48∙1) 
13 (48∙1) 
1 (3∙8) 
 
60 (40∙8) 
86 (58∙5) 
1 (0∙7) 
Primary tumor type, No. (%) 
Bladder 
Cervix 
Endometrium 
Esophagus 
NSCLC 
Ovary 
Prostate 
SCCHN 
 
2 (7∙4) 
2 (7∙4) 
3 (11∙1) 
4 (14∙8) 
4 (14∙8) 
7 (25∙9) 
4 (14∙8) 
1 (3∙8) 
 
15 (10∙2) 
34 (23∙1) 
14 (9∙5) 
15 (10∙2) 
15 (10∙2) 
36 (24∙5) 
18 (12∙3) 
– 
Number of prior therapies, median (range) 
All 
Bladder 
Cervix 
Endometrium 
Esophagus 
NSCLC 
Ovary 
Prostate 
SCCHN 
 
3 (1–14) 
– 
– 
– 
– 
– 
– 
– 
– 
 
3 (1–9) 
2 (1–5) 
2 (1–5)  
1.5 (1–5) 
2 (1–4) 
2 (1–5) 
4 (2–9) 
4 (3–7) 
– 
 
Abbreviations: ECOG=Eastern Cooperative Oncology Group; PS=performance status; SCCHN= squamous cell 
carcinoma of the head and neck.  
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Table 2. Treatment-Emergent AEs (Occurring in >10% of Patients or with Grade ≥ 3) in the Dose-Expansion 
Phase 
Preferred term 
 n=147   
Grade 1-2 Grade 3 Grade 4 Grade 5 
Any AE, No. (%) 65 (44) 78 (53∙1) 9 (6∙1) 6 (4∙1) 
Epistaxis 102 (69∙4) 0 0 0 
Nausea 74 (50∙3) 3 (2∙0) 0 0 
Fatigue 68 (46∙3) 14 (9∙5) 0 0 
Alopecia 64 (43∙5)  0 0 0 
Conjunctivitis 58 (39∙5) 5 (3∙4) 0 0 
Decreased appetite 51 (34∙7) 2 (1∙4) 0 0 
Constipation 50 (34∙0) 2 (1∙4) 0 0 
Diarrhea 42 (28∙6) 2 (1∙4) 0 0 
Vomiting 37 (25∙2) 5 (3∙4) 0 0 
Dry eye 32 (21∙8) 0 0 0 
Neuropathy peripheral 31 (21∙1) 2 (1∙4) 0 0 
Weight decreased 25 (17∙0) 0 0 0 
Abdominal pain 24 (16∙3) 6 (4∙1) 0 0 
Pruritus 22 (15∙0) 0 0 0 
Myalgia 22 (15∙0) 0 0 0 
Arthralgia 21 (14∙3) 0 0 0 
Dyspnea 21 (14∙3) 2 (1∙4) 0 0 
Rash 21 (14∙3) 1 (0∙7) 0 0 
Insomnia 20 (13∙6) 1 (0∙7) 0 0 
Back pain 18 (12∙2) 1 (0∙7) 0 0 
Cough 18 (12∙2) 0 0 0 
Headache 17 (11∙6) 0 0 0 
Hypokalemia 16 (10∙9) 6 (4∙1) 0 0 
AST increased 16 (10∙9) 1 (0∙7) 0 0 
Peripheral sensory neuropathy 13 (8∙8) 3 (2∙0) 0 0 
Pyrexia 13 (8∙8) 1 (0∙7) 0 0 
ALT increased 13 (8∙8) 2 (1∙4) 0 0 
Uncoded 13 (8∙8) 1 (0∙7) 0 0 
Hypomagnesemia 12 (8∙2) 2 (1∙4) 0 0 
Anemia 12 (8∙2) 8 (5∙4) 0 0 
Muscular weakness 11 (7∙5) 1 (0∙7) 0 0 
Urinary tract infection 10 (6∙8) 2 (1∙4) 0 0 
Mucosal inflammation 10 (6∙8) 1 (0∙7) 0 0 
Stomatitis 10 (6∙8) 1 (0∙7) 0 0 
Upper respiratory tract infection 8 (5∙4) 1 (0∙7) 0 0 
Vaginal hemorrhage 7 (4∙8) 2 (1∙4) 0 0 
Blood ALP increased 7 (4∙8) 1 (0∙7) 0 0 
Neutropenia 6 (4∙1) 3 (2∙0) 0 0 
Ulcerative keratitis 6 (4∙1) 0 1 (0∙7) 0 
Anxiety 5 (3∙4) 1 (0∙7) 0 0 
Asthenia 5 (3∙4) 1 (0∙7) 0 0 
Malaise 5 (3∙4) 1 (0∙7) 0 0 
Dehydration 4 (2∙7) 2 (1∙4) 0 0 
Hypertension 4 (2∙7) 2 (1∙4) 0 0 
Blood CPK increased 4 (2∙7) 1 (0∙7) 0 0 
Peripheral motor neuropathy 4 (2∙7) 1 (0∙7) 0 0 
Hyponatremia 3 (2∙0) 3 (2∙0) 2 (1∙4) 0 
Colitis 3 (2∙0) 2 (1∙4) 0 0 
GGT increased 3 (2∙0) 2 (1∙4) 0 0 
Lower respiratory tract infection 3 (2∙0) 2 (1∙4) 0 0 
Dysphagia 2 (1∙4) 2 (1∙4) 0 0 
Gastroenteritis 2 (1∙4) 1 (0∙7) 0 0 
Infection 2 (1∙4) 1 (0∙7) 0 0 
Polyneuropathy 2 (1∙4) 2 (1∙4) 0 0 
Tumor pain 2 (1∙4) 1 (0.7) 0 0 
Hyperglycemia 1 (0∙7) 2 (1∙4) 0 0 
Hypoacusis 1 (0∙7) 1 (0∙7) 0 0 
Hypophosphatemia 1 (0∙7) 2 (1∙4) 0 0 
Lymphocyte count decrease 1 (0∙7) 2 (1∙4) 0 0 
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Neutrophil count decrease 1 (0∙7) 1 (0∙7) 0 0 
Pulmonary embolism 1 (0∙7) 1 (0∙7) 0 0 
Hydronephrosis 0 2 (1∙4) 0 0 
Ankle fracture 0 1 (0∙7) 0 0 
Cellulitis 0 1 (0∙7) 0 0 
Clostridium difficle colitis 0 1 (0∙7) 0 0 
Corneal lesion 0 1 (0∙7) 0 0 
Demyelinating polyneuropathy 0 1 (0∙7) 0 0 
Device failure 0 1 (0∙7) 0 0 
General physical health deterioration 0 1 (0∙7) 0 2 (1∙4) 
GI hemorrhage 0 1 (0∙7) 0 0 
GI ulcer hemorrhage 0 1 (0∙7) 0 0 
Hemorrhage 0 1 (0∙7) 0 0 
Hypoxia 0 1 (0∙7) 0 0 
Ischemic stroke 0 1 (0∙7) 0 0 
Kidney infection 0 1 (0∙7) 0 0 
Medical device site hemorrhage 0 1 (0∙7) 0 0 
Metastases to central nervous system 0 1 (0∙7) 0 1 (0∙7) 
Pneumonia 0 1 (0∙7) 0 1 (0∙7) 
Postoperative wound infection 0 1 (0∙7) 0 0 
Pyelonephritis 0 1 (0∙7) 0 0 
Respiratory tract infection 0 1 (0∙7) 0 0 
Sepsis 0 1 (0∙7) 1 (0∙7) 0 
Small intestine obstruction 0 1 (0∙7) 0 0 
Stress fracture 0 1 (0∙7) 0 0 
Subileus 0 1 (0∙7) 0 0 
Tumor hemorrhage 0 1 (0∙7) 0 0 
Urethral stenosis 0 1 (0∙7) 0 0 
Urethritis 0 1 (0∙7) 0 0 
Urosepsis 0 1 (0∙7) 0 0 
Febrile neutropenia 0 0 2 (1∙4) 0 
Diabetes mellitus inadequate control 0 0 1 (0∙7) 0 
Hyperbilirubinemia 0 0 1 (0∙7) 0 
Hypoglycemia 0 0 1 (0∙7) 0 
Neutropenic sepsis 0 0 1 (0∙7) 0 
Esophageal perforation 0 0 1 (0∙7) 0 
Disease progression 0 0 0 1 (0∙7) 
Esophageal cancer metastatic 0 0 0 1 (0∙7) 
 
Abbreviations: AE=adverse event; ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate 
aminotransferase; CPK=creatine phosphokinase; GGT=gamma-glutaminetransferase; TEAE=treatment-emergent 
adverse event. 
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Table 3. Antitumor Activity in the Dose-Expansion Phase 
Response* 
All 
(n=147) 
Bladder 
(n=15) 
Cervix 
(n=34) 
Endometrium 
(n=14) 
Esophagus 
(n=15) 
NSCLC 
(n=15) 
Ovary 
(n=36) 
Prostate 
(n=18) 
ORR, No. (%)  
(95% CI) – Full analysis set
†
 
23 (15∙6) 
(10∙2–22∙5) 
4 (26∙7) 
(7∙8–55∙1) 
9 (26∙5) 
(12∙9–44∙4) 
1 (7∙1) 
(0∙2–33∙9) 
2 (13∙3) 
(1∙7–40∙5) 
2 (13∙3) 
(1∙7–40∙5) 
5 (13∙9) 
(4∙7–29∙5) 
0
‡
 
(0–0∙2) 
 
*Confirmed responses per RECIST, per investigator review. Six patients in the prostate cohort did not have measurable disease at baseline, therefore responses 
were evaluated by PSA levels. 
†
The full analysis set was comprised of patients who were exposed to study drug. 
‡
Neither radiographic imaging or PSA levels 
indicated a response in these patients. 
Abbreviation: ORR=overall response rate. 
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Figure 1. Patient enrollment and disposition in innovaTV 201 (dose escalation and expansion). 
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Figure 2. Maximum percentage reduction in tumor size in the various expansion study cohorts recruiting 
patients with bladder, cervix, endometrium, esophagus, NSCLC, ovary, and prostate cancers. 
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Figure 3. Duration of response in individual responders. 
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Patient Recruitment 
Patients were recruited across 3 sites (Denmark [n=1]; United Kingdom [n=1], United States [n=1]) for the dose-
escalation portion and 21 sites (Belgium [n=6]; Denmark [n=2]; Sweden [n=1]; United Kingdom [n=9]; United 
States [n=3]) for the expansion portion.  
 
Site Name Principal Investigator Number of Patients Enrolled 
Dose-escalation Phase 
Royal Marsden Hospital Johann de Bono 11 
Rigshospitalet Ulrik Lassen 9 
The University of Texas MD Anderson Cancer 
Center 
David S Hong 7 
Dose-expansion Phase 
Universitair Ziekenhuis Leuven Multidisciplinair 
Borstcenturm 
Nicole Concin 17 
The Christie NHS Foundation- Clinical Trial 
Pharmacy 
Emma Dean 13 
The University of Texas MD Anderson Cancer 
Center 
David S Hong 12 
Rigshospitalet Ulrik Lassen 11 
Newcastle Hospitals NHS Foundation Trust Ruth Plummer 10 
Sarah Cannon Research Institute London Hendrik-Tobias Arkenau 10 
Royal Marsden Hospital Johann de Bono 9 
Clinique Universitaires Saint-Luc Jean-Pascal Machiels 9 
Valindre NHS Trust Robert Hugh Jones 9 
Herlev and Gentofte Hospital Dorte Nielsen 7 
University College London Hospitals Martin David Forster 7 
University of Miami Brian Slomovitz 6 
Sarah Cannon Research Institute-Cincinnati Melissa Johnson 6 
Karolinska University Hospital Solna Jeffrey Yachin 5 
Guy’s and Saint Thomas’ NHS Foundation Trust James F Spicer 5 
Beatson Cancer Centre Glasgow Robert Hugh Jones  4 
Centre Hospitalier Universitaire de Liège Christine Gennigens 2 
The Leeds Teaching Hospitals NHS Trust Chris Twelves 2 
Centre Hospitalier Universitaire Ambroise Paré Stephane Holbrechts 1 
Grand Hôpital de Charlerai- Notre Dame Jean-Luc Canon 1 
CHU UCL NAMAR- Sainte Elisabeth Jean-Charles Goeminne 1 
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Table S1. Treatment-Emergent AEs (Occurring in >10% of Patients or with Grade ≥ 3) in the Dose-
Escalation Phase  
Preferred term 
 
All Doses 
(n=27) 
  
Grade 1–2 Grade 3 Grade 4 Grade 5 
Any AE, No. (%) 8 (30) 16 (59)  0 3 (11) 
Epistaxis 13 (48) 0 0 0 
Fatigue 9 (33) 4 (15) 0 0 
Pyrexia 8 (30) 0 0 0 
Constipation 8 (30) 0 0 0 
Alopecia 8 (30) 0 0 0 
Nausea 8 (30) 0 0 0 
Decreased appetite 7 (26) 0 0 0 
Anemia 7 (26) 4 (15) 0 0 
Diarrhea  5 (19) 1 (4) 0 0 
Arthralgia  5 (19) 0 0 0 
Mucosal inflammation  4 (15) 1 (4) 0 0 
Pruritus  4 (15) 0 0 0 
Rash (maculopapular)  4 (15) 0 0 0 
Nasal congestion  4 (15) 0 0 0 
Hypokalemia  4 (15) 1 (4) 0 0 
Vomiting  4 (15) 0 0 0 
ALT increased  4 (15) 0 0 0 
Vision blurred  4 (15) 0 0 0 
Headache  4 (15) 0 0 0 
Hematuria  4 (15) 0 0 0 
Tachycardia  4 (15) 0 0 0 
Urinary tract infection  4 (15) 0 0 0 
Abdominal pain  3 (11) 3 (11) 0 0 
Conjunctivitis  3 (11) 0 0 0 
Conjunctival hemorrhage  3 (11) 0 0 0 
Neuropathy peripheral  3 (11) 0 0 0 
Rash  3 (11) 0 0 0 
Weight decrease  3 (11) 0 0 0 
Back pain  3 (11) 0 0 0 
Dyspnea  2 (7) 1 (4) 0 0 
Transaminase increased  2 (7) 1 (4) 0 0 
Pain in extremity  2 (7) 1 (4) 0 0 
Lymphocyte count decreased  1 (4) 1 (4) 0 0 
Ascites  1 (4) 2 (7) 0 0 
Hyponatremia  0 3 (11) 0 0 
Intestinal obstruction  0 2 (7) 0 0 
Gastritis  0 1 (4) 0 0 
Small intestine obstruction  0 1 (4) 0 0 
Cystitis escherichia  0 1 (4) 0 0 
Diabetes mellitus  0 1 (4) 0 0 
Klebsiella infection  0 1 (4) 0 0 
Febrile neutropenia  0 1 (4) 0 0 
Guillain-barre syndrome  0 1 (4) 0 0 
Acute kidney injury  0 1 (4) 0 0 
Platelet count decreased  0 1 (4) 0 0 
Disease progression  0 0 0 2 (7) 
Pharyngeal hemorrhage  0 0 0 1 (4) 
 
Abbreviation: AE=adverse event. 
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Table S2. Treatment-Emergent Serious Adverse Events (Occurring in >1% of Patients)  
in the Dose-Expansion Phase  
Preferred term n=147 
Any serious adverse event, No. (%) 67 (45∙6) 
Vomiting 6 (4∙1) 
Abdominal pain 5 (3∙4) 
Anemia 4 (2∙7) 
Hematuria 3 (2∙0) 
Constipation 3 (2∙0) 
Diarrhea 3 (2∙0) 
General physical health deterioration  3 (2∙0) 
Hyponatremia 3 (2∙0) 
Infection 3 (2∙0) 
Malaise 2 (1∙4) 
Vaginal hemorrhage 2 (1∙4) 
Colitis 2 (1∙4) 
Conjunctivitis 2 (1∙4) 
Dysphagia 2 (1∙4) 
Febrile neutropenia 2 (1∙4) 
Hypokalemia 2 (1∙4) 
Lower respiratory tract infection 2 (1∙4) 
Metastases to central nervous system 2 (1∙4) 
Nausea 2 (1∙4) 
Pneumonia 2 (1∙4) 
Sepsis 2 (1∙4) 
Urinary tract infection 2 (1∙4) 
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Table S3. Incidence of Neuropathy Adverse Events in the Dose-Expansion Phase  
Preferred term 
n=147 
All Grade Grade ≥3 
Any neuropathy event, No. (%)    63 (42∙9)  10 (6∙8) 
Neuropathy peripheral    33 (22∙4)   2 (1∙4) 
Peripheral sensory neuropathy    16 (10∙9)   3 (2∙0) 
Muscular weakness 12 (8∙2)   1 (0∙7) 
Peripheral motor neuropathy   5 (3.4)   1 (0∙7) 
Paresthesia    4 (2∙7) 0 
Polyneuropathy   4 (2∙7)   2 (1∙4) 
Dysesthesia   3 (2∙0) 0 
Gait disturbance   2 (1∙4) 0 
Hypoesthesia   2 (1∙4) 0 
Demyelinating polyneuropathy    1 (0∙7)   1 (0∙7) 
Guillain-Barré syndrome   1 (0∙7) 0 
Muscular atrophy   1 (0∙7) 0 
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Table S4. Incidence of Ocular Adverse Events in the Dose-Expansion Phase 
Preferred term All Patients (n=147) Before mitigation (n=77) After mitigation (n=70) 
 All Grade Grade ≥3 Patients AEs, No. Patients AEs, No. 
Any ocular event, No. (%)* 88 (59∙9) 5 (3∙4) 50 (64∙9) 85 38 (54∙3) 79 
Conjunctivitis 63 (42∙9) 5 (3∙4) 43 (55∙8) 59 20 (28∙6) 31 
Dry eye 32 (21∙8) 0 13 (16∙9) 15 19 (27∙1) 20 
Conjunctival ulcer 6 (4∙1) 0 1 (1∙3) 1 5 (7∙1) 5 
Conjunctival hyperemia 4 (2∙7) 0 0 0 4 (5∙7) 5 
Conjunctival scar 4 (2∙7) 0 1 (1∙3) 1 3 (4∙3) 3 
Keratitis  4 (2∙7) 0 1 (1∙3) 2 3 (4∙3) 3 
Noninfective conjunctivitis 4 (2∙7) 0 1 (1∙3) 1 3 (4∙3) 3 
Conjunctival hemorrhage 3 (2∙0) 0 3 (3∙9) 5 0 0 
Symblepharon 3 (2∙0) 0 0 0 3 (4∙3) 3 
Conjunctival disorder 2 (1∙4) 0 0 0 2 (2∙9) 3 
Seasonal allergy 2 (1∙4) 0 1 (1.3) 1 1 (1∙4) 1 
Conjunctival staining  1 (0∙7) 0 0 0 1 (1∙4) 1 
Conjunctivitis allergic  1 (0∙7) 0 0 0 1 (1∙4) 1 
 
*Most patients with conjunctivitis experienced other ocular events.  
Abbreviation: AE=adverse event. 
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Table S5. Pharmacokinetic Parameters of Tisotumab Vedotin by Dose Cohort After a Single Dose 
Dose level (mg/kg) Patients, No. 
AUC
0-t
 C
max
 t
max
 
Mean 
(h·µg/mL) 
CV 
(%) 
Mean 
(µg/mL) 
CV 
(%) 
Mean 
(h) 
CV 
(%) 
0∙3 3 59∙2 3∙1 4∙8 12∙4 1∙5 72∙7 
0∙6 3 368∙4 8∙2 12∙2 9∙5 1∙2 13∙0 
0∙9 3 601∙9 16∙9 19∙8  17∙3 1∙3 11∙8 
1∙2 3 1084∙7 9∙3 34∙7 18∙5 1∙2 11∙7 
1∙5 3 795∙0 19∙0 23∙1 21∙1 1∙1 9∙6 
1∙8 3 1504∙8 49∙5 35∙4 39∙2 1∙2 14∙3 
2∙0 3 1256∙4 33∙1 32∙3 22∙1 1∙2 7∙5 
2∙2 6 2037∙1 33∙7 55∙5 10∙3 1∙1 12∙5 
 
Abbreviations: AUC0-t = area under the concentration time curve; Cmax=maximum concentration; CV=coefficient of 
variation; t
max
=time to reach maximum concentration. 
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Table S6. Antitumor Activity by Dose Cohort in the Dose-Escalation Phase 
Response Evaluation* All Doses 
(n=27) 
0∙3 mg/kg 
(n=3) 
0∙6 mg/kg 
(n=3) 
0∙9 mg/kg 
(n=3) 
1∙2 mg/kg 
(n=3) 
1∙5 mg/kg 
(n=3) 
1∙8 mg/kg 
(n=3) 
2∙0 mg/kg 
(n=3) 
2∙2 mg/kg 
(n=6) 
PR, No. (%) 1 (3∙7) 0 0      0 1 (33∙3) 0 0 0 0 
SD, No. (%) 11 (40∙7) 0 1 (33∙3) 1 (33∙3) 1 (33∙3) 0 3 (100) 1 (33∙3) 4 (66∙7) 
PD, No. (%) 14 (51∙9) 3 (100.0) 1 (33∙3) 2 (66∙7) 1 (33∙3) 3 (100) 0 2 (66∙7) 2 (33∙3) 
NE,
†
 No. (%) 1 (3∙7) 0 1 (33∙3) 0 0 0 0 0 0 
 
*Confirmed responses per RECIST, per investigator review. †Patient died prior to first scan. 
NE=not evaluable; PD=progressive disease; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease. 
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Figure S1. Mean plasma concentration-time profiles for tisotumab vedotin and free MMAE at cycle 1 by 
dose-escalation cohort. 
 
 
 
Three patients were included in dose cohorts ranging from 0∙3 to 2∙0 mg/kg, while six patients were included in the 
2∙2-mg/kg dose cohort.  
Abbreviations: LLOQ=lower limit of quantitation; MMAE=monomethyl auristatin E.  
 
  
10 
 
Figure S2. Prothrombin time (PT) and activated partial thromboplastin time in dose-expansion phase.  
 
Black line indicates the median value. The shaded region and error bars indicate the IQR. 
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Full Study Protocol 
The remainder of the web appendix is dedicated to the approved study protocol. 
 
